Therapeutic cloning uses a laboratory technique called somatic cell nuclear transfer (SCNT) to create embryonic stem cells that are genetically matched to a specific patient. Unlike reproductive cloning, the goal is never to produce a new organism; instead, the cloned embryo is developed only to the blastocyst stage, at which point stem cells are harvested for potential medical use. The technique has been demonstrated in primates and in human cells, but it remains technically demanding, ethically contested, and far from routine clinical application.
How the Process Works
The basic procedure has been consistent since its early demonstrations. A researcher collects a mature egg cell (oocyte) from a donor and removes its nucleus, stripping out nearly all of the egg’s own DNA. A body cell, often a skin cell called a fibroblast, is then taken from the patient. The nucleus of that body cell is transferred into the emptied egg. The egg’s internal machinery then reprograms the transplanted nucleus, effectively resetting it from its specialized adult state back toward an embryonic-like state. Protocols typically involve oocyte collection, in vitro maturation, enucleation, and nuclear transfer using fibroblast or cumulus cell donors.1PubMed Central. Protocol for somatic cell nuclear transfer in the common marmoset
What happens inside the egg after nuclear transfer is remarkable. The egg’s cytoplasm contains a cocktail of factors that strip away the adult cell’s identity. Somatic proteins are exchanged for oocyte proteins, chemical tags on histones are modified, and DNA methylation patterns are erased and rewritten.2PubMed Central. Mechanisms of nuclear reprogramming by eggs and oocytes: a deterministic process? This reprogramming is what allows a cell that was once committed to being, say, a skin cell to start behaving as if it were part of a newly formed embryo. If everything goes right, the reconstructed egg begins dividing and forms a blastocyst within about five to seven days. The inner cell mass of that blastocyst is the source of embryonic stem cells.
What Makes It Different from Reproductive Cloning
The distinction matters enormously for both the science and the ethics. Therapeutic cloning creates a line of embryonic stem cells genetically identical to an individual, while reproductive cloning creates a new organism genetically identical to an individual.3Nature Reports Stem Cells. What’s the difference between cloning embryonic stem cells and cloning a new organism? In practice, the laboratory steps are nearly identical up to the blastocyst stage. The divergence comes in what happens next. In reproductive cloning, the blastocyst would be implanted into a uterus to develop into a full organism. In therapeutic cloning, the blastocyst is never implanted. Instead, stem cells are extracted, destroying the blastocyst in the process. This destruction is the crux of many ethical objections, which we will get to.
Because the nuclear DNA in these stem cells comes from the patient, the cells are a near-perfect genetic match. That is the therapeutic promise: tissues or cells grown from them should, in theory, be accepted by the patient’s immune system without the need for immunosuppressive drugs. The word “near-perfect” is important, though, because the match is not truly complete. The egg donor contributes mitochondrial DNA, which introduces a subtle genetic mismatch that can have real immunological consequences.
What Has Actually Been Achieved in the Lab
Therapeutic cloning in primates was demonstrated when researchers used a modified SCNT approach to produce rhesus macaque blastocysts from adult skin fibroblasts and successfully isolated two embryonic stem cell lines from those embryos.4Nature. Producing primate embryonic stem cells by somatic cell nuclear transfer That was a significant proof-of-concept moment, showing that adult primate cells could be reprogrammed back to a fully pluripotent state through nuclear transfer.
More recently, researchers working with common marmosets have pushed the technique further. By injecting mRNA for a histone demethylase called Kdm4d, they achieved blastocyst formation in about 15% of attempts using fibroblasts. Adding a histone methyltransferase inhibitor improved blastocyst quality enough to derive nuclear transfer embryonic stem cell lines, including transgenic ones, with normal chromosome counts and confirmed pluripotency.5PubMed Central. Derivation of embryonic stem cells from cloned blastocysts using improved somatic cell nuclear transfer in common marmosets These primate results are meaningful because the jump from mouse to primate SCNT has historically been a major stumbling block.
In human cells, success has also been reported. Overexpression of a related demethylase, KDM4A, improved the blastocyst formation rate dramatically in human SCNT embryos and enabled derivation of stem cell lines from adult patient cells, including cells from individuals with age-related macular degeneration.6PubMed. Histone Demethylase Expression Enhances Human Somatic Cell Nuclear Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells In those experiments, about 27% of KDM4A-injected embryos reached the blastocyst stage by day six, compared to roughly 4% of controls.7Cell Stem Cell. Histone Demethylase KDM4A Overexpression Promotes Human Somatic Cell Nuclear Transfer Efficiency and Derivation of Pluripotent Stem Cells That is a real improvement, but it still means most attempts fail.
The Epigenetic Reprogramming Barrier
The reason therapeutic cloning remains so inefficient comes down to how thoroughly the egg can erase the donor cell’s identity. Adult cells carry extensive chemical modifications on their DNA and histone proteins that lock genes into tissue-specific patterns. The egg needs to wipe much of this slate clean. One of the biggest obstacles turns out to be a specific histone modification called H3K9me3, a mark that keeps genes tightly shut off. In both mouse and human SCNT, regions of the donor genome stubbornly retain this mark, preventing the normal wave of gene activation that should happen in early embryonic development.
The KDM4A and Kdm4d demethylases mentioned above work by specifically removing H3K9me3 marks, allowing genes to reactivate on schedule. This discovery reframed the efficiency problem from a vague “reprogramming failure” into a concrete molecular target, which has guided much of the recent technical progress. Even so, the blastocyst formation rates in primates and human cells remain far below what fertility clinics achieve with standard in vitro fertilization, underscoring how imperfect the reprogramming still is.
The Mitochondrial Problem
One of the selling points of therapeutic cloning is immune compatibility. Because the nuclear DNA matches the patient, tissues derived from these stem cells should look like “self” to the immune system. But cells do not just have nuclear DNA. Every cell also carries mitochondria, each with its own small genome inherited from the egg donor, not from the patient. Research has shown that this mismatch matters more than initially hoped.
In a mouse transplantation model, stem cells derived by nuclear transfer that were nucleus-identical to the recipient but carried mismatched mitochondria triggered an adaptive immune response that impaired graft survival.8Cell Stem Cell. Mitochondria-Derived Alloantigenicity Dictates Tumor Rejection in Embryonic Stem Cell Grafts Derived by Somatic Cell Nuclear Transfer The immune system recognized proteins encoded by the foreign mitochondrial DNA and mounted a rejection response against them. The researchers noted that this response was amenable to tolerance induction, meaning it could potentially be managed, but it complicates the narrative that therapeutic cloning produces perfectly matched cells.9Cell Stem Cell. SCNT-Derived ESCs with Mismatched Mitochondria Trigger an Immune Response in Allogeneic Hosts
One workaround would be to use eggs from the patient herself, or from a maternal relative with matching mitochondrial DNA. But this introduces its own practical and ethical complications, as it limits who can donate eggs and further constrains an already difficult supply chain.
How SCNT Compares to Induced Pluripotent Stem Cells
Since 2006, a competing technology has attracted most of the stem cell field’s attention. Induced pluripotent stem cells (iPSCs) are made by introducing a handful of reprogramming factors into adult cells, turning them back into a stem-cell-like state without eggs, embryos, or nuclear transfer. iPSCs sidestep many of the ethical and logistical hurdles of therapeutic cloning, which has led some researchers to wonder whether SCNT-based approaches are still worth pursuing.
The answer depends on how you measure quality. Studies comparing stem cells made by nuclear transfer with those made by iPSC reprogramming have found that SCNT-derived cells more closely resemble naturally fertilized embryonic stem cells at the epigenetic level. In one analysis, iPSCs had roughly 60 times more sites where their DNA methylation patterns differed from standard embryonic stem cells, compared to nuclear-transfer stem cells. About one in ten of those differences in iPSCs could be traced to leftover “epigenetic memory” of the original adult cell type.10STEM CELLS. Concise Review: Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer: A Horse in the Race? By that measure, the egg’s reprogramming machinery does a more thorough job of resetting a cell than the handful of transcription factors used to make iPSCs.
However, a separate study using cells from the same genetic background (isogenic comparisons) found that once iPSCs and SCNT-derived stem cells were differentiated into specific cell types like heart cells or blood vessel cells, the functional differences largely disappeared. The differentiated cells showed comparable gene expression, physiological properties, and metabolic function, with genetic background mattering more than the reprogramming method.11PubMed Central. Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs This suggests that for many practical applications, iPSCs may be good enough, even if SCNT cells are more pristine at the stem cell stage.
The upshot is that SCNT remains the gold standard for complete epigenetic reprogramming, which matters for research applications and for certain therapeutic contexts where subtle epigenetic differences could affect cell behavior. But for most foreseeable clinical uses, iPSCs have emerged as the more practical option, largely because they avoid the need for human eggs and embryo destruction.
Potential Medical Applications
The therapeutic vision for SCNT goes beyond simply growing replacement tissues. Because the technique can generate patient-specific pluripotent stem cells, it opens several doors. Cells could be directed to become dopamine-producing neurons for Parkinson’s disease, insulin-secreting cells for diabetes, or cardiomyocytes for heart failure. The fact that these cells carry the patient’s own nuclear genome should reduce rejection risk and eliminate the need for lifelong immunosuppression, which is a major source of complications in organ transplantation.
Beyond direct cell replacement, SCNT-derived stem cells could serve as disease models. If you take skin cells from a patient with a genetic disease and create embryonic stem cells through nuclear transfer, you can then differentiate those cells into the tissue type affected by the disease, essentially recreating the disease in a dish. This allows researchers to study disease mechanisms and screen potential drugs in cells that carry the exact genetic makeup of a real patient. The technique also holds potential for breeding transgenic animals for biomedical applications, such as producing human-compatible organs or modeling human diseases in animal systems.12PubMed Central. Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era
Animal studies have provided early evidence for some of these applications. In one experiment, mouse embryonic stem cells derived by SCNT were used with a temperature-responsive gel to treat heart tissue damage in rats, showing improvement in cardiac function.13PubMed. Both the transplantation of somatic cell nuclear transfer- and fertilization-derived mouse embryonic stem cells with temperature-responsive chitosan hydrogel improve myocardial performance in infarcted rat hearts But moving from animal models to human patients has been slow, partly because of technical difficulties and partly because the ethical landscape has constrained funding and regulatory approval.
The Central Ethical Debate
The core ethical tension is straightforward to state, even if it is impossible to resolve to everyone’s satisfaction. Therapeutic cloning requires creating a human blastocyst and then destroying it to extract stem cells. Whether that blastocyst constitutes a human life, or at least a being with moral status, is the question that divides opinions.
Opponents argue that creating and destroying embryos for research purposes is equivalent to taking human life, regardless of the medical potential. This position draws on arguments about the moral status of the embryo that have been debated for decades in the context of abortion and embryo research.14Journal of Biotechnology. Ethical dimensions of therapeutic human cloning Proponents counter that a blastocyst at five days old, consisting of roughly 100 to 200 cells with no nervous system or capacity for sensation, does not warrant the same moral consideration as a sentient being, and that the potential to treat devastating diseases justifies the procedure.15Stem Cell Research and Regenerative Medicine. Therapeutic Cloning: Potential, Challenges, and Ethical Considerations
Neither side has a monopoly on moral seriousness, and this is not the sort of disagreement that more data can resolve. It rests on foundational beliefs about personhood and the beginning of moral status, which are philosophical commitments, not empirical questions.
The Slippery Slope Concern
Even among people who accept the use of early embryos for research, a persistent worry is that allowing therapeutic cloning will inevitably lead to or facilitate reproductive cloning. The reasoning goes that once laboratories routinely create cloned blastocysts, the infrastructure and expertise to implant one into a uterus would exist, and preventing someone from taking that step would become impossible.16PubMed Central. Is a consensus possible on stem cell research? Moral and political obstacles
Defenders of therapeutic cloning respond that the same argument could be leveled against many technologies. Fertility clinics already create surplus embryos during IVF, and the existence of that capability has not led to widespread embryo misuse. The distinction, they argue, lies in regulation and intent, not in the technology itself. Still, the slippery slope concern has been influential in shaping legislation, with some countries banning all forms of human cloning rather than attempting to draw a line between therapeutic and reproductive applications.
The Egg Donation Question
A less discussed but practically significant ethical issue involves the sourcing of human oocytes. Every attempt at therapeutic cloning requires at least one mature egg, and collecting eggs from women involves hormone injections to stimulate the ovaries, followed by a retrieval procedure. The most debated medical risk is ovarian hyperstimulation syndrome (OHSS), a condition in which the ovaries overreact to the hormones. A review of the evidence on OHSS in egg donation concluded that the risk is not significant enough to warrant undue concern when proper precautions are taken.17PubMed. Assessing the risk of ovarian hyperstimulation syndrome in egg donation: implications for human embryonic stem cell research
But the ethical dimension goes beyond physical risk. If therapeutic cloning were ever to scale up, the demand for eggs would be enormous. Questions about compensation, informed consent, and potential exploitation of egg donors, particularly women from lower-income backgrounds who might be motivated primarily by payment, are genuine concerns. These issues do not have clean answers, and they sit alongside the embryo debate as a separate ethical domain that any clinical program would need to address.
Regulation Around the World
The legal landscape for therapeutic cloning is fractured. A survey of national regulations found that while most countries have enacted legislation on cloning, the rules vary widely. Nearly all countries examined ban reproductive cloning. The treatment of therapeutic (or “non-reproductive”) cloning is far less uniform: while it is explicitly prohibited in many countries, it could be permitted in up to thirteen of the countries surveyed.18PubMed Central. Variations and voids: the regulation of human cloning around the world Some countries have no national legislation on the topic at all, though that does not necessarily mean the practice is unregulated, since other institutional or professional guidelines may apply.
The United Kingdom has been among the most permissive, allowing therapeutic cloning under a licensing framework. The United States has no federal ban but has restricted federal funding for human embryo research, effectively pushing the work into privately funded laboratories. Several countries, including Germany and France, have taken more restrictive stances, prohibiting the creation of embryos for research purposes. This patchwork means that the pace and direction of research depend heavily on where a laboratory is located.
Public Attitudes and the Framing Problem
Surveys of public opinion reveal a consistent pattern: people view therapeutic cloning more favorably than reproductive cloning, but both tend to provoke unease. Research into British public attitudes found that quantitative surveys showed more positive responses than focus groups, where participants were generally negative about both forms. Therapeutic cloning was accepted more readily when the medical benefits were made clear. Attitudes correlated more strongly with underlying values about scientific progress than with demographic factors like age, gender, or education, and while religious affiliation showed some association, the effects were small.19PubMed. Towards an understanding of British public attitudes concerning human cloning
This suggests that how therapeutic cloning is described matters as much as what it actually involves. The word “cloning” itself carries enormous baggage, invoking science fiction imagery that has little to do with the reality of growing a ball of cells in a dish. Some researchers have advocated for alternative terminology, such as “somatic cell nuclear transfer for stem cell derivation,” precisely to separate the technique from its cultural connotations. Whether that kind of rebranding is honest framing or strategic euphemism is itself a small ethical debate.
Where SCNT Fits in the Broader Stem Cell Landscape
Therapeutic cloning occupies a peculiar position in biomedical research. It remains the most thorough method for reprogramming adult cells, producing stem cells that are epigenetically closer to natural embryonic stem cells than any competing technique. But it is also the most logistically demanding, ethically fraught, and technically inefficient approach. iPSCs have taken over much of the translational space, with multiple iPSC-based therapies now in clinical trials for conditions ranging from macular degeneration to Parkinson’s disease. Direct reprogramming methods, which convert one mature cell type into another without passing through a stem cell stage, are also advancing.
SCNT’s enduring value may be less as a direct clinical tool and more as a research platform. It provides a benchmark against which other reprogramming methods can be measured, and it offers unique capabilities for studying early embryonic development, epigenetic reprogramming, and nuclear-cytoplasmic interactions. The technique also retains applications in animal cloning for conservation, agriculture, and the production of biomedical model organisms.12PubMed Central. Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era Whether it will ever be used routinely to treat patients depends on whether the technical hurdles continue to fall, whether the mitochondrial compatibility problem can be solved, and whether societies decide the ethical costs are acceptable given the alternatives now available.